Pfizer swings to loss as COVID product demand slump sparks charges
© Reuters. FILE PHOTO: Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease , is displayed in this picture illustration taken October 7, 2022. REUTERS/Wolfgang Rattay/Illustration/File Photo -Pfizer on Tuesday reported its first quarterly loss since 2019, as demand fell for its COVID products and it recorded a hefty charge mainly from the U.S. government returning millions of doses of its antiviral treatment Paxlovid. The company recorded a $5.
"Despite a messy quarter with many moving parts, we continue to believe that Pfizer's products and pipeline remain under-appreciated," said Cantor Fitzgerald analyst Louise Chen. The company posted a loss of 42 cents per share for the third quarter. It had reported a profit of $1.51 per share in the year-ago quarter.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer swings to quarterly loss due to COVID products write-offPfizer (PFE.N) on Tuesday reported its first quarterly loss since 2019, as the U.S. drugmaker recorded $5.6 billion in charges related to its COVID products such as its antiviral treatment Paxlovid and vaccine Comirnaty.
Weiterlesen »
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offsThe results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.
Weiterlesen »
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offsThe results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.
Weiterlesen »
A continuing decline in sales of COVID-19 products clips revenue at PfizerPfizer losses were not as great as expected in the third quarter, but a continued decline in sales of its COVID-19 products clipped revenue. Pfizer reported a $2.38 billion quarterly loss Tuesday, or 42 cents per share.
Weiterlesen »
Pfizer posts narrower Q3 loss amid slumping Covid vaccine salesPfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
Weiterlesen »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underway
Weiterlesen »